作为潜在抗抑郁药的TWIK-1/TREK-1异构体的新型强效阻断剂
Elliot H Lee1, Jung-Eun Park2, Lizaveta Gotina3
1Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea; Department of Anesthesiology and Pain Medicine, SMG-SNU Boramae Medical Center, College of Medicine, Seoul National University, Seoul, Republic of Korea.
研究人员确定了抑制TWIK-1/TREK-1异构体的新型化合物,在小鼠中显示出类似抗抑郁药的效果. 这表明TWIK-1/TREK-1异构体是抗抑郁药物开发的有希望的新标.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- TREK-1 (TWIK相关通道-1) 是大脑表达的K2p通道子单元.
- TREK-1淘汰赛小鼠表现出类似抗抑郁药的效果,表明其治疗潜力.
- 缺乏针对具有抗抑郁作用的TREK-1通道的特定药理抑制剂.
研究的目的:
- 为了发现TREK-1相关二分体的选择性和强效抑制剂.
- 在体外和体内评估这些抑制剂的抗抑郁药类活性.
- 为了确定抗抑郁药疗法的新分子标.
主要方法:
- 合成和评价的2-基-3-基烯酸皮佩里丁衍生物.
- 在体外和体外测试,包括强迫游泳和尾部悬浮测试.
- 分子对接模拟以分析与TREK-1同位体和TWIK-1/TREK-1异位体的化合物相互作用.
主要成果:
- 化合物2a,2g和2h强烈抑制TREK-1同位体和TWIK-1/TREK-1异位体,表现出类似抗抑郁药的效果.
- 抑制TWIK-1/TREK-1异构剂与抗抑郁药效应正相关.
- 现有的抗抑郁药素也抑制了TWIK-1/TREK-1异构体.
结论:
- 新型强效TWIK-1/TREK-1抑制剂 (2a,2g,2h) 被确定为潜在的抗抑郁药.
- TWIK-1/TREK-1异构体代表了抗抑郁药物潜在的新型分子治疗点.
- 选择性抑制TWIK-1/TREK-1异构体可能是抗抑郁药疗效的关键.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
09:10DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
Published on: July 22, 2022
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: Overview
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Drugs Affecting Neurotransmitter Release or Uptake
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
